Advancements in molecular and translational allergology: Safety and immunogenicity of chemically modified peanut allergens and nanoparticle-based delivery system

H.J.M. Warmenhoven

Advancements in molecular and translational allergology: Safety and immunogenicity of chemically modified peanut allergens and nanoparticle-based delivery system

H.J.M. Warmenhoven

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

In 1911, the first evidence of successful, disease modifying, allergen-specific immunotherapy (AIT) was published. Currently, there is still a lot of room for improving AIT to make this treatment the first choice for allergologists. Because of the high risk of allergic side-effects, the first aim of this thesis was to explore a safe AIT concept for peanut allergy. The second aim was to explore the

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	van Ree, Ronald, Supervisor van Rijt, Leonie, Co-supervisor
Award date	4 Dec 2024
Print ISBNs	9789493278837
Publication status	Published - 2024

Access to Document

https://pure.uva.nl/ws/files/201197402/Thesis.pdf

Cite this

@phdthesis{9ca4a7cbc2a9468aa57927a5ea0860cd,

title = "Advancements in molecular and translational allergology: Safety and immunogenicity of chemically modified peanut allergens and nanoparticle-based delivery system",

abstract = "In 1911, the first evidence of successful, disease modifying, allergen-specific immunotherapy (AIT) was published. Currently, there is still a lot of room for improving AIT to make this treatment the first choice for allergologists. Because of the high risk of allergic side-effects, the first aim of this thesis was to explore a safe AIT concept for peanut allergy. The second aim was to explore the",

author = "H.J.M. Warmenhoven",

year = "2024",

language = "English",

isbn = "9789493278837",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - Advancements in molecular and translational allergology

T2 - Safety and immunogenicity of chemically modified peanut allergens and nanoparticle-based delivery system

AU - Warmenhoven, H.J.M.

PY - 2024

Y1 - 2024

N2 - In 1911, the first evidence of successful, disease modifying, allergen-specific immunotherapy (AIT) was published. Currently, there is still a lot of room for improving AIT to make this treatment the first choice for allergologists. Because of the high risk of allergic side-effects, the first aim of this thesis was to explore a safe AIT concept for peanut allergy. The second aim was to explore the

AB - In 1911, the first evidence of successful, disease modifying, allergen-specific immunotherapy (AIT) was published. Currently, there is still a lot of room for improving AIT to make this treatment the first choice for allergologists. Because of the high risk of allergic side-effects, the first aim of this thesis was to explore a safe AIT concept for peanut allergy. The second aim was to explore the

M3 - Phd-Thesis - Research and graduation internal

SN - 9789493278837

ER -

Advancements in molecular and translational allergology: Safety and immunogenicity of chemically modified peanut allergens and nanoparticle-based delivery system

Abstract

Access to Document

Fingerprint

Cite this